Stage (next event)
Phase 2 (Top-line Data)
Catalyst Info & Data Links
TITLE: VLA15 for Lyme Disease - Phase 2 Top-line Data
Phase 2 - ClinicalTrial.gov (NCT03769194) Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.
Phase 1 - ClinicalTrial.gov (NCT03010228) Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis
WHAT IS THE NEXT CATALYST EVENT?
Phase 2 Top-line Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Q4 2020 (see slide 21)
2019: A PHASE 1 STUDY ASSESSING THE SAFETY, IMMUNOGENICITY AND DOSE-RESPONSE OF VLA15, A MULTIVALENT RECOMBINANT OSPA-BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS, IN HEALTHY ADULTS AGED BELOW 40 YEARS. 2019 International Society for Vaccines Annual Congress, Ghent, October 27–29
2017: Comstedt, P., Schüler, W., Meinke, A., & Lundberg, U. (2017). The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes. PloS one, 12(9), e0184357.
MECHANISM OF ACTION / RATIONALE
VLA15 is a multivalent, protein subunit vaccine that targets the outer surface protein A (OspA) of Borrelia, an established mechanism of action for Lyme disease vaccine. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick (learn more HERE).
Updated by HC
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post